Tenax Therapeutics Inc

Insider buying at Tenax Therapeutics signals confidence in its PH‑HFpEF levosimendan pipeline—explore why executives see long‑term upside despite current losses.

Insider buy signals confidence in Tenax Therapeutics’ levosimendan‑based pulmonary hypertension drug, highlighting Phase 3 readiness and FDA‑approved IND milestones.

Insider buying at Tenax Therapeutics signals confidence amid volatility, hinting a Phase‑3 data boost could lift stock—learn why it matters.

Insider June Sherie’s purchase of 30,000 zero‑exercise options highlights confidence in Tenax Therapeutics’ levosimendan pulmonary‑hypertension pipeline, suggesting a potential valuation boost once clinical milestones arrive.

Tenax Therapeutics insider buying signals confidence as the company’s new pulmonary hypertension therapy edges toward FDA Fast Track status, hinting at future upside.